Abstract 1564P
Background
With over 2 million cases diagnosed annually, breast cancer is a leading cause of cancer-related disability and mortality worldwide. Despite global efforts to implement screening programs, uptake rates vary widely across settings due to socioeconomic factors and accessibility challenges. In 2022 in Flanders (Belgium), breast cancer screening participation in municipalities with income below the poverty line was 15% lower than average.
Methods
To tackle the limited participation of low-SES women in the breast cancer screening program in Flanders, a culturally sensitive approach was used to realize a tailored reminder letter.
33 women (of which 29 non-native Dutch speakers) aged 50-69 with low-SES were identified with the assistance of community organizations to conduct Focus Group Discussions (FGDs). Through a series of 4 FGDs and 3 rounds of Delphi-consultations involving sector experts, valuable insights were gathered.
Results
Analysis of the standard invitation letter employed in the program revealed several challenges related to readability and comprehension. These included the excessive length of the text, the use of complex vocabulary and grammar beyond an A2 level, the inclusion of contextual sentences unrelated to the mammography appointment (“We do it. And what do you do?”), and the use of generic visuals (eg. a picture of women).
At the same time, simplifying the vocabulary to A1-A2 levels (“cancer”, “doctor”, “appointment”, “check”, “free”), employing straightforward sentence structures, and incorporating relevant visuals (e.g. image of a mammography machine) enhanced understandability and fostered interest in breast cancer prevention. Additionally, utilizing a color palette associated with breast cancer and featuring logos of local authorities instilled a sense of credibility and trustworthiness.
Conclusions
Based on feedback from sector experts and insights from the FGDs, a revised reminder letter was developed. The final communication was concise and included essential details such as time and place for screening, as well as a QR code providing translation into 12 languages.
To assess its efficacy in increasing participation rates, a RCT with 3,430 participants per arm is currently being conducted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Stichting tegen Kanker.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10